GW Henssler & Associates Ltd. Reduces Holdings in GSK plc (NYSE:GSK)

GW Henssler & Associates Ltd. reduced its stake in shares of GSK plc (NYSE:GSK) by 13.0% in the 4th quarter, HoldingsChannel reports. The firm owned 16,407 shares of the pharmaceutical company’s stock after selling 2,442 shares during the quarter. GW Henssler & Associates Ltd.’s holdings in GSK were worth $555,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. FMR LLC grew its stake in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares during the period. Fisher Asset Management LLC boosted its holdings in shares of GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares during the last quarter. Clifford Capital Partners LLC grew its position in shares of GSK by 14.3% in the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after purchasing an additional 51,378 shares during the period. Cerity Partners LLC increased its stake in GSK by 61.8% in the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after purchasing an additional 165,556 shares during the last quarter. Finally, Natixis Advisors LLC lifted its position in GSK by 20.0% during the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after buying an additional 83,433 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Trading Down 0.4 %

Shares of GSK stock opened at $35.20 on Monday. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The firm’s 50 day moving average price is $34.07 and its two-hundred day moving average price is $37.68. The stock has a market cap of $72.96 billion, a price-to-earnings ratio of 22.86, a price-to-earnings-growth ratio of 1.38 and a beta of 0.64. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

Analyst Ratings Changes

GSK has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. StockNews.com downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Finally, Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and lowered their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Six research analysts have rated the stock with a hold rating, one has given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.